Rice University logo
 
Top blue bar image
Moake Laboratory in Hemostasis-Thrombosis Research
Investigating the molecular processes that link hemostasis-thrombosis and inflammation
 

Publications

Publications (Selected from 225 total, 1967 – present)

  1. Nascimbene A, Neelamegham S, Frazier OH, Moake JL, Dong JF. Acquired von Willebrand syndrome associated with left ventricular assist device. Blood. 2016; 127: 3133-3141.
  2. Sartain SE, Turner NA, Moake JL. TNF Regulates Essential Alternative Complement Pathway Components and Impairs Activation of Protein C in Human Glomerular Endothelial Cells. J Immunol. 2016; 196: 832-845.
  3. Wijeratne SS, Li J, Yeh HC, Nolasco L, Zhou Z, Bergeron A et al. Single-molecule force measurements of the polymerizing dimeric subunit of von Willebrand factor. Phys Rev E. 2016; 93: 012410.
  4. Turner N, Sartain S, Moake J. Ultralarge Von Willebrand Factor-Induced Platelet Clumping and Activation of the Alternative Complement Pathway in Thrombotic Thrombocytopenic Purpura and the Hemolytic-Uremic Syndromes. Hematol Oncol Clin North Am. 2015; 29(3): 509-524.
  5. Turner NA, Moake JL. Factor VIII Is Synthesized in Human Endothelial Cells, Packaged in Weibel-Palade Bodies and Secreted Bound to ULVWF Strings. PLoS One. 2015; 10: e0140740.
  6. Turner NA, Sartain SE, Hui SK, Moake JL. Regulatory components of the alternative complement pathway in endothelial cell cytoplasm, factor h and factor I, are not packaged in weibel-palade bodies. PLoS One. 2015; 10: e0121994.
  7. Balaoing LR, Post AD, Lin AY, Tseng H, Moake JL, Grande-Allen KJ. Laminin Peptide-Immobilized Hydrogels Modulate Valve Endothelial Cell Hemostatic Regulation. PLoS One. 2015; 10: e0130749.
  8. Turner N, Nolasco L, Nolasco J, Sartain S, Moake J. Thrombotic microangiopathies and the linkage between von Willebrand factor and the alternative complement pathway. Semin Thromb Hemost. 2014; 40: 544-550.
  9. Li GW, Rambally S, Kamboj J, Reilly S, Moake JL, Udden MM, Mims MP. Treatment of refractory thrombotic thrombocytopenic purpura with N-acetylcysteine: a case report. Transfusion. 2014; 54: 1221-1224.
  10. Turner NA, Moake J. Assembly and activation of alternative complement components on endothelial cell-anchored ultra-large von Willebrand factor links complement and hemostasis-thrombosis. PLoS One. 2013; 8: e59372.
  11. Nolasco L, Nolasco J, Feng S, Afshar-Kharghan V, Moake J. Human complement factor H is a reductase for large soluble von Willebrand factor multimers–brief report. Arterioscler Thromb Vasc Biol. 2013; 33: 2524-2528.
  12. Wijeratne SS, Botello E, Yeh HC, Zhou Z, Bergeron AL, Frey EW et al. Mechanical activation of a multimeric adhesive protein through domain conformational change. Phys Rev Lett. 2013; 110: 108102.
  13. Feng S, Kroll MH, Nolasco L, Moake J, Afshar-Kharghan V. Complement activation in thrombotic microangiopathies. Br J Haematol. 2013; 160(3): 404-406.
  14. Lo NC, Turner NA, Cruz MA, Moake J. Interaction of Shiga toxin with the A-domains and multimers of von Willebrand Factor. J Biol Chem. 2013; 288: 33118-33123.
  15. Turner N, Nolasco L, Moake J. Generation and Breakdown of Soluble Ultralarge von Willebrand Factor Multimers. Semin Thromb Hemost. 2012; 38: 38-46.
  16. Tsai M, Kita A, Leach J, Rounsevell R, Huang JN, Moake J et al. In vitro modeling of the microvascular occlusion and thrombosis that occur in hematologic diseases using microfluidic technology. J Clin Invest. 2012; 122: 408-418.
  17. Hui SR, Turner N, Surratt C, Rossmann SN, Moake J, Teruya J. Comparison and Stability of Factor H in Plasma-Containing Blood Components. Transfusion. 2011; 51: 48A-49A.
  18. Chen J, Reheman A, Gushiken FC, Nolasco L, Fu X, Moake JL et al. N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice. J Clin Invest. 2011; 121: 593-603.
  19. Turner NA, Nolasco L, Ruggeri ZM, Moake JL. Endothelial cell ADAMTS-13 and VWF: production, release, and VWF string cleavage. Blood. 2009; 114: 5102-5111.
  20. Turner N, Nolasco L, Dong JF, Moake J. ADAMTS-13 cleaves long von Willebrand factor multimeric strings anchored to endothelial cells in the absence of flow, platelets or conformation-altering chemicals. J Thromb Haemost. 2009; 7: 229-232.
  21. Nolasco LH, Gushiken FC, Turner NA, Khatlani TS, Pradhan S, Dong JF et al. Protein phosphatase 2B inhibition promotes the secretion of von Willebrand factor from endothelial cells. J Thromb Haemost. 2009; 7: 1009-1018.
  22. Auton M, Cruz MA, Moake J. Conformational stability and domain unfolding of the Von Willebrand factor A domains. J Mol Biol. 2007; 366: 986-1000.
  23. Moake JL. Journey in reverse: TTP from bedside to blood bank to bench. J Clin Apher. 2007; 22: 37-49.
  24. Tao Z, Anthony K, Peng Y, Choi H, Nolasco L, Rice L et al. Novel ADAMTS-13 mutations in an adult with delayed onset thrombotic thrombocytopenic purpura. J Thromb Haemost. 2006; 4: 1931-1935.
  25. Turner N, Nolasco L, Tao Z, Dong JF, Moake J. Human endothelial cells synthesize and release ADAMTS-13. J Thromb Haemost. 2006; 4: 1396-1404.
  26. Moake JL (2006) TTP and HUS. editor. Platelets.
  27. Nolasco LH, Turner NA, Bernardo A, Tao Z, Cleary TG, Dong JF, Moake JL. Hemolytic uremic syndrome-associated Shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers. Blood. 2005; 106: 4199-4209.
  28. Tao Z, Peng Y, Nolasco L, Cal S, Lopez-Otin C, Li R et al. Recombinant CUB-1 domain polypeptide inhibits the cleavage of ULVWF strings by ADAMTS13 under flow conditions. Blood. 2005; 106: 4139-4145.
  29. Bernardo A, Ball C, Nolasco L, Choi H, Moake JL, Dong JF. Platelets adhered to endothelial cell-bound ultra-large von Willebrand factor strings support leukocyte tethering and rolling under high shear stress. J Thromb Haemost. 2005; 3: 562-570.
  30. Bernardo A, Ball C, Nolasco L, Moake JF, Dong JF. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood. 2004; 104: 100-106.
  31. Dong JF, Moake JL, Bernardo A, Fujikawa K, Ball C, Nolasco L et al. ADAMTS-13 metalloprotease interacts with the endothelial cell-derived ultra-large von Willebrand factor. J Biol Chem. 2003; 278: 29633-29639.
  32. Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002; 347: 589-600.
  33. Arya M, Anvari B, Romo GM, Cruz MA, Dong JF, McIntire LV et al. Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: studies using optical tweezers. Blood. 2002; 99: 3971-3977.
  34. Dong JF, Moake JL, Nolasco L, Bernardo A, Arceneaux W, Shrimpton CN et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood. 2002; 100: 4033-4039.
  35. Turner NA, Moake JL, McIntire LV. Blockade of adenosine diphosphate receptors P2Y(12) and P2Y(1) is required to inhibit platelet aggregation in whole blood under flow. Blood. 2001; 98: 3340-3345.
  36. Fredrickson BJ, Turner NA, Kleiman NS, Graziadei N, Maresh K, Mascelli MA et al. Effects of abciximab, ticlopidine, and combined Abciximab/Ticlopidine therapy on platelet and leukocyte function in patients undergoing coronary angioplasty. Circulation. 2000; 101: 1122-1129.
  37. Chow TW, Turner NA, Chintagumpala M, McPherson PD, Nolasco LH, Rice L et al. Increased von Willebrand factor binding to platelets in single episode and recurrent types of thrombotic thrombocytopenic purpura. Am J Hematol. 1998; 57: 293-302.
  38. Konstantopoulos K, Chow TW, Turner NA, Hellums JD, Moake JL. Shear stress-induced binding of von Willebrand factor to platelets. Biorheology. 1997; 34: 57-71.
  39. Moake J, Chintagumpala M, Turner N, McPherson P, Nolasco L, Steuber C et al. Solvent/detergent-treated plasma suppresses shear-induced platelet aggregation and prevents episodes of thrombotic thrombocytopenic purpura. Blood. 1994; 84: 490-497.
  40. Alevriadou BR, Moake JL, Turner NA, Ruggeri ZM, Folie BJ, Phillips MD et al. Real-time analysis of shear-dependent thrombus formation and its blockade by inhibitors of von Willebrand factor binding to platelets. Blood. 1993; 81: 1263-1276.
  41. Chow TW, Hellums JD, Moake JL, Kroll MH. Shear stress-induced von Willebrand factor binding to platelet glycoprotein Ib initiates calcium influx associated with aggregation. Blood. 1992; 80: 113-120.
  42. Frangos JA, Moake JL, Nolasco L, Phillips MD, McIntire LV. Cryosupernatant regulates accumulation of unusually large vWF multimers from endothelial cells. Am J Physiol. 1989; 256: H1635-44.
  43. Moake JL, McPherson PD. Abnormalities of von Willebrand factor multimers in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. Am J Med. 1989; 87: 9N-15N.
  44. Kroll MH, Harris TS, Moake JL, Handin RI, Schafer AI. von Willebrand factor binding to platelet GpIb initiates signals for platelet activation. J Clin Invest. 1991; 88: 1568-1573.
  45. Moake JL, Turner NA, Stathopoulos NA, Nolasco L, Hellums JD. Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or unusually large vWF multimers, requires adenosine diphosphate, and is resistant to aspirin. Blood. 1988; 71: 1366-1374.
  46. Phillips MD, Moake JL, Nolasco L, Turner N. Aurin tricarboxylic acid: a novel inhibitor of the association of von Willebrand factor and platelets. Blood. 1988; 72: 1898-1903.
  47. Peterson DM, Stathopoulos NA, Giorgio TD, Hellums JD, Moake JL. Shear-induced platelet aggregation requires von Willebrand factor and platelet membrane glycoproteins Ib and IIb-IIIa. Blood. 1987; 69: 625-628.
  48. Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Hellums JD. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest. 1986; 78: 1456-1461.
  49. Moake JL, Byrnes JJ, Troll JH, Rudy CK, Hong SL, Weinstein MJ, Colannino NM. Effects of fresh-frozen plasma and its cryosupernatant fraction on von Willebrand factor multimeric forms in chronic relapsing thrombotic thrombocytopenic purpura. Blood. 1985; 65: 1232-1236.
  50. Moake JL, Rudy CK, Troll JH, Weinstein MJ, Colannino NM, Azocar J et al. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med. 1982; 307: 1432-1435.